A new vaccine that reduces genital herpes outbreaks could soon be available
Thomson Reuters
However, researchers from Indiana University have created a vaccine that could reduce the number of genital herpes outbreaks a person experiences in a year, reports MedPage Today.
The vaccine could make life a lot easier for people who suffer from genital herpes, in addition to potentially reducing transmission of the disease.
The vaccine - known as GEN-OO3 - just successfully went through a phase II clinical trial, with patients seeing a 60% reduction in outbreaks a year after receiving the therapeutic treatment.
Genital herpes sufferers can currently take daily medications to reduce their outbreaks, but scientists say this vaccine could be a revolutionary treatment.
"It would allow them to reduce viral shedding and lesion formation for at least a year without taking medication every day," Indiana researcher Dr. Kenneth Fife told MedPage Today.
The trial included 310 patients who were randomly assigned to six possible dose combinations or to a placebo.
They were each given three shots, three weeks apart, and genital swabs were collected twice a day for the first 28 days before the vaccination, as well as at six and 12 months after the trial.
Dr. Lynn Enquist, of Princeton University and president of the American Society of Microbiology, told MedPage Today that "the results look promising at this stage - reactivation and lesion formation in patients were reduced compared to placebo injections."
And so, Dr. Enquist said, the vaccine suggested that "a safe, effective immunotherapy for recurrent genital herpes is possible."
GEN-OO3 still needs to receive FDA approval before it can be available to patients, but if the drug makes it that far, it would be the first vaccine for genital herpes, the drugmaker Genocea said on its website.
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- FSSAI in process of collecting pan-India samples of Nestle's Cerelac baby cereals: CEO
- Indian economy remains in bright spot: Ministry of Finance
- A surprise visit: Tesla CEO Elon Musk heads to China after deferring India visit
- Unemployment among Indian youth is high, but it is transient: RBI MPC member
- Private Equity Investments
- Having an regional accent can be bad for your interviews, especially an Indian one: study
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market